In a nutshell The authors looked at increasing the dose of rituximab for elderly male patients with diffuse large B-cell lymphoma. The authors concluded that the higher dose improved patient outcomes and was just as safe as the lower dose. Some background Diffuse large B-cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma. It is...
Read MoreNon-Hodgkin lymphoma Posts on Medivizor
Rituximab, bendamustine, and low-dose cytarabine treatment for elderly patients with mantle cell lymphoma
In a nutshell This study looked at the safety and effectiveness of rituximab (Rituxan), bendamustine (Treanda), and low-dose cytarabine (Cytosar) for treating elderly patients with mantle cell lymphoma. The study concluded that this treatment is effective at treating elderly patients with mantle cell lymphoma, but has some adverse events. Some...
Read MoreEffectiveness of idelalisib treatment for patients with relapsed or refractory follicular lymphoma
In a nutshell This study looked at the safety and effectiveness of idelalisib treatment for patients with relapsed or difficult to treat follicular lymphoma. The study concluded that idelalisib can be used safely to treat these patients. Some background Follicular lymphoma (FL) is an incurable type of non-Hodgkin lymphoma. Patient outcomes...
Read MoreUsing 18F-FDG PET scans to determine future outcomes for patients with mantle cell lymphoma
In a nutshell This study looked at how well 18F-FDG positron emission tomography (PET) scans can determine future patient outcomes for patients with relapsed or difficult to treat mantle cell lymphoma. The study concluded that 18F-FDG PET scans can determine future patient outcomes, and negative PET scans indicate positive outcomes. Some...
Read MoreBendamustine plus rituximab to treat patients with indolent B-cell lymphoma or mantle cell lymphoma
In a nutshell This study looked at how effective the combination of bendamustine plus rituximab was at treating patients with indolent B-cell non-Hodgkin lymphoma (B-NHL) and mantle cell lymphoma (MCL). The study concluded that bendamustine plus rituximab is safe and effective for treating patients with indolent B-NHL and MCL. Some...
Read MoreUsing obintuzumab plus CHOP or bendamustine to treat patients with follicular lymphoma
In a nutshell This study compared the effectiveness of obinutuzumab (Gazyva) plus CHOP chemotherapy vs obinutuzumab plus bendamustine (Treanda) in treating patients with follicular lymphoma. The study concluded that both obinutuzumab plus CHOP and obinutuzumab plus bendamustine are effective at treating patients with follicular...
Read MoreTreatment options for double-hit diffuse large B-cell lymphoma
In a nutshell This study looked at the best treatment options for patients with double-hit diffuse large B-cell lymphoma. The study concluded that patients with double-hit lymphoma have better outcomes when treated with more intense regimens. Some background Diffuse large B-cell lymphoma (DLBCL) is a common type of non-Hodgkin lymphoma. There are...
Read MoreObinutuzumab vs rituximab treatment for patients with advanced stage follicular lymphoma
In a nutshell This study compared rituximab (Rituxan)-based treatment to obinutuzumab (Gazyva)-based treatment in patients with advanced stage follicular lymphoma. The study concluded that obinutuzumab-based therapy leads to longer progression-free survival. Some background Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma...
Read MoreA review of rituximab maintenance treatment for patients with diffuse large B-cell lymphoma
In a nutshell This study examined the effectiveness of rituximab maintenance treatment for patients with diffuse large B-cell lymphoma (DLBCL). The review concluded that rituximab maintenance treatment increases progression-free survival in patients with DLBCL. Some background Diffuse large B-cell lymphoma (DLBCL) is a common type of...
Read MoreAutologous stem cell transplantation in patients with mantle cell lymphoma
In a nutshell This study compared the effectiveness of autologous stem cell transplantation in patients with mantle cell lymphoma who either did or did not achieve a complete response after first line treatment. The study concluded that autologous stem cell transplantation is most useful for patients who have already achieved a complete...
Read MoreIf Not For Immunotherapy…
“I’m barely 27 and if it were not for immunotherapy and cancer research, I would not have seen 25.” So starts Stefanie Joho speech at a 2017 Congressional Hearing called “Progress in Immunotherapy: Delivering Hope and Clinical Benefit to Cancer Patients.” When Stefanie was 22, she was diagnosed with a very aggressive Stage II...
Read MoreThe use of rituximab maintenance therapy after autologous stem cell transplantation for patients with mantle cell lymphoma
In a nutshell This study looked at the effect of rituximab maintenance therapy for mantle cell lymphoma patients who have already received an autologous stem cell transplantation. The study concluded that rituximab maintenance therapy greatly improves outcomes for patients with mantle cell lymphoma. Some background Mantle cell lymphoma (MCL)...
Read More
